RxDoctor Payments Data

Seth Wheeler, MD

Gastroenterology · Twin Falls, IDNPI 1548222516

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 51.5% of the total. Reporting peaked in 2019 at $872 and has fallen 97.1% since, to $26 in 2023. That places this record below the midpoint for gastroenterology clinicians in ID, where the typical reported total is $1,538.

$1,133in general payments, 2019–2025

Across 81 payments — averaging $13.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$583
  • Braintree Laboratories, Inc.$97
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86
  • Pfizer$83
  • Gilead$71
  • Johnson & Johnson$35
  • plus $178 from 8 others

What the payments were for

  • Food & beverage$1,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,133 in reported general payments places this provider in the 45th percentile of 70 gastroenterology providers in Idaho.

See all gastroenterology providers in Idaho

Medicare billing

Part B allowed, 2024
$83,777
Medicare patients
398
Services billed
712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin13$40,174
RelistorMethylnaltrexone Bromide13$29,644
CreonLipase/Protease/Amylase27$27,424
LinzessLinaclotide26$21,507
Budesonide EcBudesonide24$13,385
Budesonide DrBudesonide44$5,297
Ursodiol21$4,320
ClenpiqSod Picosulf/Mag Ox/Citric Ac12$2,011
Omeprazole137$1,649
Pantoprazole Sodium55$1,340
Carvedilol29$152
Prednisone12$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor$86$69,81826 claims
AbbVieCreon, Linzess$583$48,93153 claims
Ferring Pharmaceuticals Inc.Clenpiq$26$2,01112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 70 gastroenterology providers in Idaho.

Other gastroenterology in Twin Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →